Research analysts at StockNews.com started coverage on shares of Avinger (NASDAQ:AVGR – Get Rating) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the medical device company’s stock.
Separately, HC Wainwright initiated coverage on shares of Avinger in a report on Friday, April 21st. They issued a “buy” rating for the company.
Avinger Price Performance
AVGR stock opened at $0.59 on Friday. The business has a 50-day moving average price of $0.64 and a 200 day moving average price of $1.00. The company has a market capitalization of $6.28 million, a P/E ratio of -0.19 and a beta of 1.52. Avinger has a 1-year low of $0.42 and a 1-year high of $2.14.
Hedge Funds Weigh In On Avinger
Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC bought a new position in Avinger in the second quarter worth about $42,000. Dimensional Fund Advisors LP acquired a new position in shares of Avinger during the first quarter valued at about $64,000. Finally, Armistice Capital LLC acquired a new position in shares of Avinger during the third quarter valued at about $768,000. 14.14% of the stock is currently owned by institutional investors.
Avinger, Inc is a commercial-stage medical device company, which engages in the designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease. Its products include Pantheris, Lightbox, Ocelot, Wildcat, Juicebox, and Kittycat.
- Get a free copy of the StockNews.com research report on Avinger (AVGR)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.